NCT06847932

Brief Summary

Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14,726

participants targeted

Target at P75+ for not_applicable

Timeline
5mo left

Started Jul 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Jul 2025Oct 2026

First Submitted

Initial submission to the registry

February 21, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 26, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

1 year

First QC Date

February 21, 2025

Last Update Submit

November 16, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Latent atrial fibrillation

    The primary outcome, latent atrial fibrillation, is a composite of new diagnoses of AF/AFL, atrial arrhythmia with high AF risk, including PACs ≥ 500/24hr, burst PACs \> 20 beats, and non-sustained AF/AFL, within 90 days after enrollment. The results will be demonstrated as the rate of diagnoses of latent atrial fibrillation.

    Within 90 days after enrollment.

Secondary Outcomes (3)

  • Antiarrhythmic treatment

    Within 180 days after enrollment.

  • 90-days New diagnoses of atrial fibrillation/atrial flutter

    Within 90 days after enrollment.

  • Atrial arrhythmia with high AF risk

    Within 90 days after enrollment.

Study Arms (2)

AF-predict AI-ECG alert system

EXPERIMENTAL

All the patients' ECGs will receive AF-predict AI-ECG analysis. According to the AI-ECG analysis results, those with at least one high-risk ECG within one year will be called back and asked to undergo a continuous cardiac rhythm monitor for up to 7 days. Otherwise, the physicians can review the AI-ECG analysis results for all the patients in the intervention group.

Other: AF-predict AI-ECG alert system guided management

Standard of care

NO INTERVENTION

Patients will receive the standard care, and their ECGs will not be analyzed by AI-ECG before the end of the study.

Interventions

AF-predict AI-ECG alert system

AF-predict AI-ECG alert system

Eligibility Criteria

Age40 Days - 85 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Patients in the inpatient department or the outpatient department
  • Patients need to have at least one electrocardiogram within one year

You may not qualify if:

  • Diagnosis of atrial fibrillation/atrial flutter
  • History of atrial fibrillation/atrial flutter catheter ablation
  • Patients with cardiac implantable electronic devices
  • Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
  • History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
  • Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tri-Service General Hospital

Taipei, 114, Taiwan

RECRUITING

MeSH Terms

Conditions

Atrial FibrillationAtrial Premature Complexes

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsCardiac Complexes, PrematureCardiac Conduction System Disease

Study Officials

  • Chin Lin, PhD

    National Defense Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 21, 2025

First Posted

February 26, 2025

Study Start

July 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

November 19, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations